The metastatic prostate cancer market was valued at USD 8.43 Billion in 2024 driven by the rising prevalence of cancer across the 8 major markets. The market is anticipated to grow at a CAGR of 8.10% during the forecast period 2025-2034 to reach a value of USD 18.37 Billion by 2034.
Base Year
Historical Year
Forecast Year
The increasing incidence of metastatic prostate cancer and a growing aging population is driving the demand for advanced treatments and personalised therapies in the market.
Increased FDA approvals for new therapies accelerate market growth by introducing innovative treatments, enhancing patient access, and encouraging ongoing research and development.
The market growth is driven by continuous advancement in treatment modalities, including the development of targeted therapies, immunotherapies, and personalised medicine.
Value in USD Billion
2025-2034
Metastatic Prostate Cancer Market Outlook
*this image is indicative*
Metastatic prostate cancer is characterised by the growth of cancerous cells outside the prostate. There are several treatment therapies for treating the condition. Hormone therapy slows or blocks prostate cancer cells from growing. Chemotherapy kills cancer cells, and it is an important treatment option for metastatic prostate cancer when the disease has metastasized (spread). Other treatment options include immunotherapy, checkpoint inhibitors, and systemic radiation treatments.
Rising Prevalence Drives Market Growth
The market growth is driven by the rising prevalence of prostate cancer. Prostate cancer is the second-leading cause of cancer death in men in the United States of America. The American Cancer Society reported around 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023. The organization has estimated that nearly 299,010 new cases and about 35,250 prostate cancer-related deaths will occur in the United States in 2024. The market growth can also be attributed to the growing geriatric population of older people. The combination of factors is creating a sense of urgency to introduce innovative and effective systemic therapies to cater to patients suffering from the disease and improve patient outcomes.
Surge in FDA Approvals to Meet Rising Metastatic Prostate Cancer Market Demand
The market is witnessing significant FDA approvals to bring innovative treatments in the market. For instance, in August 2023, the combination of niraparib and abiraterone acetate (Akeega) with prednisone was approved by the FDA for men with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer. The approval was expedited and granted under the priority review designation. The approval of new and innovative therapies in the market increases the range of treatment options available. The accelerated approval process highlights the FDA's support for innovative treatments, encouraging further investment and development in metastatic prostate cancer treatment, and fuelling market development.
Research and Clinical Trials Bolstering Market Growth
The market growth is poised to be fuelled by the ongoing research into novel therapies, including targeted drugs, immunotherapies, and combination treatments. For instance, in July 2024, Bayer revealed that its drug Nubeqa was found to be effective in slowing the progression of a certain type of prostate cancer in a late-stage trial, underpinning growth prospects. Nubuqa in combination with androgen deprivation therapy significantly delayed progression-free survival in comparison to the androgen deprivation therapy alone in a phase III trial. This development is expected to boost Nubeqa's clinical performance and escalate its use among healthcare providers to treat advanced prostate cancer, leading to higher adoption rates.
The market is witnessing several trends and developments to improve the global current scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Rising Prevalence and Geriatric Population | The market is witnessing a rising incidence of prostate cancer including metastatic or advanced prostate cancer. The growing geriatric population is collectively driving demand for effective treatments in the treatment market for the disease. |
| Advancement in Treatment Options | The market has seen a significant shift towards personalised medicine, with targeted therapies and immunotherapies gaining substantial traction. Hormonal therapies and combination therapies are becoming the standard treatment for metastatic cancers due to their effectiveness. |
| Increasing Use of Genetic Testing and Biomarkers | The escalation in the development and demand for personalised treatments as they are based on genetic testing is boosting the market, helping personalised therapies treat individual patients. |
| FDA Approvals Expanding Pipeline | A strong pipeline of new metastatic or advanced prostate cancer drugs can be witnessed as there are several under development, with many receiving expedited FDA approvals, ensuring quicker access to innovative treatments. |
Market Breakup by Treatment Type
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Country
Segmentation Based on Treatment Type Anticipated to Witness Growth
The market segmentation based on treatment type includes chemotherapy, immunotherapy, hormonal therapy, radiation therapy, and others. Hormonal therapy is expected to lead the market share due to its effectiveness in targeting androgen hormones. The high prevalence of hormone-sensitive metastatic prostate cancer is a major factor driving its dominance in the market.
Metastatic Prostate Cancer Market Analysis by Region
Based on region, the market report is divided into the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan and India. The United States dominates the market due to several factors. The country has a high incidence of prostate cancer highly driven by an aging population and increasing diagnostic practices, contributing to a large patient pool requiring advanced treatments. The United States healthcare system also supports the rapid adoption of innovative therapies, bolstered by substantial investment in research and development. The market dominance can be attributed to the presence of leading pharmaceutical companies and research institutions facilitating continuous advancements in treatment options, including targeted therapies and immunotherapies, which are increasingly personalised using biomarkers and genetic testing.
Additionally, the U.S. FDA's proactive regulatory environment, which includes expedited approval pathways like Priority Review and Breakthrough Therapy Designation, ensures that cutting-edge treatments reach the market faster than in other regions. The country's robust healthcare infrastructure, combined with strong reimbursement frameworks, enables broader patient access to these high-cost, and advanced therapies. Moreover, high patient awareness and engagement in clinical trials contribute to the rapid adoption of new treatments. These factors collectively justify the United States as the leading regional market for metastatic prostate cancer, driving both innovation and market growth.
The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
AstraZeneca is a global, science-led biopharmaceutical company that has made significant strides in oncology, including metastatic prostate cancer. Their portfolio includes Lynparza (olaparib), a PARP inhibitor used in metastatic prostate cancer patients with specific genetic mutations like BRCA1/2. Lynparza represents a targeted therapy approach, offering personalized treatment options that extend survival in patients with advanced prostate cancer.
Pfizer is a leading global pharmaceutical corporation with a diverse portfolio in oncology. It offers Xtandi (enzalutamide), a next-generation androgen receptor inhibitor that has become a standard treatment for both metastatic and non-metastatic prostate cancer. Xtandi works by blocking the effects of androgens, which fuel the growth of prostate cancer cells and is widely used in combination with other therapies to improve patient outcomes.
Sanofi is a global healthcare leader with a strong presence in the oncology field, including metastatic prostate cancer. Their portfolio includes Jevtana (cabazitaxel), a chemotherapy drug used in patients with advanced prostate cancer who have previously been treated with docetaxel. Jevtana is often utilized in cases where the disease has progressed despite prior treatments, offering a critical option for prolonging survival in late-stage metastatic prostate cancer patients.
Bristol Myers Squibb (BMS) is a global biopharmaceutical company known for its innovative cancer treatments. In the metastatic prostate cancer market, BMS is focused on immunotherapy, with Opdivo (nivolumab) being a key component of their portfolio. Although Opdivo is more commonly associated with other cancers, BMS is actively exploring its potential in combination with other agents to treat metastatic prostate cancer, particularly in patients with high mutational burdens or other specific biomarkers.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include F-Hoffmann-La Roche Ltd, Daiichi Sankyo Inc., AB Science, Teva Pharmaceutical Industries Ltd, and Eli Lily and Company.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share